Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Offers optional dual IBP, and EtCo 2 — Now with Masimo SET ® Pulse Oximetry! The fully-functional Waveline Touch features a 12.1" color TFT display with a touch-screen interface. It features ...

Masimo sells a range of devices used for patient monitoring that feature a proprietary pulse oximetry technology called Signal Extraction Technology (SET). In the latest update on that patent spat ...

With President-elect Donald Trump proposing tariffs as high as 60%- 100% on goods imported from China, Wall Street analysts ...

The dispute dates to 2013 when Apple sought Masimo’s technology to install pulse oximetry on its watch. Email correspondence ...

Raymond James raised Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target on the stock in a report on Wednesday. Wells Fargo & Company boosted ...

Revenue: US$504.6m (up 5.4% from 3Q 2023). Net income: US$9.80m (down 7.5% from 3Q 2023). Profit margin: 1.9% (down from 2.2% in 3Q 2023). The decrease in margin was driven by higher expenses. EPS ...

Unrecognized Contract Revenues: $1.65 billion as of the end of Q3. Masimo Corp (NASDAQ:MASI) reported healthcare revenues of $343 million for the third quarter, representing a 12% growth compared ...

Piper Sandler raised the firm’s price target on Masimo (MASI) to $180 from $165 and keeps an Overweight rating on the shares. The firm notes the company announced Q3 revenue of $505M finished ...